Specifically, targeting the KEAP1-NRF2 axis could have dual applications: reactivating KEAP1 to suppress NRF2 hyperactivation in advanced cancers or modulating NRF2 activity to protect normal tissues from oxidative damage during cancer therapy. Here, KEAP1 is linked to cancer.